It has a broad spectrum of antimicrobial effects, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis; it only has antibacterial effects on anaerobic bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis, etc. Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus are usually resistant to chloramphenicol. This product is an antibacterial agent that reversibly binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis. It has a strong immunosuppressive effect, about 6 times stronger than chloramphenicol. It is completely cross-resistant with chloramphenicol.

This product can compete with histamine released from tissues for the H26 receptors on effector cells, thereby preventing the onset of allergic reactions and relieving the spasmodic and congestive effects of histamine.

This product is a drug that inhibits the synthesis of uric acid. Allopurinol and its metabolite oxypurinol can inhibit xanthine oxidase, preventing hypoxanthine and xanthine from being metabolized into uric acid, thereby reducing the production of uric acid. It reduces the uric acid content in the blood and urine to a level below the solubility, prevents uric acid from forming crystals and depositing in joints and other tissues, and also helps to redissolve uric acid crystals in the tissues of gout patients. Allopurinol also inhibits the synthesis of new purines in the body by acting on hypoxanthine-guanine phosphate nucleic acid transferase. The blood uric acid concentration begins to decrease 24 hours after oral administration of this product, and the decrease is most obvious in 2 to 4 weeks.

Erythromycin is a macrolide antibiotic. Its mechanism of action is to inhibit bacterial protein synthesis. It has antibacterial effects on Gram-positive bacteria and Chlamydia trachomatis.